Today: 7 February 2026
Subscribe

Marcin Frąckiewicz

CEO of TS2 Space and founder of TS2.tech. Expert in satellites, telecommunications, and emerging technologies, covering trends in space, AI, and connectivity.

Cipher Mining (CIFR) Stock Skyrockets on AI Pivot & Bitcoin Boom – Next Crypto Powerhouse?

Cipher Mining (CIFR) Stock Skyrockets on AI Pivot & Bitcoin Boom – Next Crypto Powerhouse?

Company Overview: Operations & Business Model Cipher Mining Inc. is a pure-play Bitcoin miner operating industrial-scale data centers with a focus on ultra-low-cost powerts2.tech. The company strategically locates its facilities in regions with cheap, renewable-rich electricity (e.g. West Texas), often building behind-the-meter or adjacent to wind and solar farmsts2.techts2.tech. Its flagship “Black Pearl” site near Odessa, TX is a 150 MW facility designed for both Bitcoin mining and high-performance computing (HPC) workloadsts2.tech. As of mid-2025, Cipher’s deployed hashrate reached about 16.8 EH/s (exahashes per second), using next-gen ASIC machines for high energy efficiencyts2.tech. The company had aggressively expanded capacity – a 2.6 GW development pipeline of power projects positions Cipher for further growthts2.tech.
8 October 2025
····
Adaptimmune Therapeutics (ADAP) Stock Skyrockets 42% – Is This Biotech Turnaround for Real?

Adaptimmune Therapeutics (ADAP) Stock Skyrockets 42% – Is This Biotech Turnaround for Real?

Therapy (Target) Indication Status (2025) Current Ownership TECELRA(afamitresgene, targets MAGE-A4) Synovial sarcoma (unresectable/metastatic) FDA approved Aug 2024 Biospace; ~16 patients treated in launch year Nasdaq. Sold to US WorldMeds (2025) Adaptimmune Letetresgene (lete-cel, NY-ESO-1) MRCLS and synovial sarcoma (advanced solid tumors) Phase II completed (42% response rate) Stocktitan; FDA Breakthroughdesignation in 2025 Stocktitan; BLA filing planned for 2025. Sold to US WorldMeds (2025) Adaptimmune Uzatresegene (uza-cel, next-gen TCR) Solid tumors (MAGE-A4 TCR, partnered with Galapagos) Preclinical/IND-enabling stage; partnership deal $665M signed 2024 Fiercebiotech. Sold to US WorldMeds (2025) Adaptimmune PRAME-targeted TCR Multiple cancers (PRAME antigen) Preclinical (IND-enabling on hold to cut costs) Biospace. Retained by Adaptimmune Adaptimmune CD70-targeted TCR Hematologic malignancies
8 October 2025
·····
Snowflake Stock Soars on AI Boom – Inside SNOW’s 2025 Rally and What’s Next

Snowflake Stock Soars on AI Boom – Inside SNOW’s 2025 Rally and What’s Next

Below, we dive deeper into each of these areas – from Snowflake’s business model and financials to the latest news, analyst insights, competitive dynamics, and what to expect going forward. Company Overview and Business Model Snowflake Inc. is a cloud data platform provider, offering data warehousing as a service alongside a suite of data analytics and sharing capabilities. Unlike traditional databases tied to a single cloud or on-premises, Snowflake’s platform is cloud-agnostic – it runs across Amazon AWS, Microsoft Azure, and Google Cloud, allowing customers to unify their data in one system regardless of cloud providermarkets.chroniclejournal.com. This flexibility has been a major selling point
8 October 2025
····
CrowdStrike Stock Skyrockets Amid Cybersecurity Boom – Is the Rally Justified? (2025 Update)

CrowdStrike Stock Skyrockets Amid Cybersecurity Boom – Is the Rally Justified? (2025 Update)

Sources: Official company reports and press releases; Yahoo Finance and Zacks Investment Research; Reuters and CNBC interviews; TS2 Tech stock analysis and cybersecurity newsts2.technasdaq.commarkets.financialcontent.commarketbeat.comts2.techsiliconangle.comts2.tech. These provide the latest financial data, expert commentary, and industry context as of October 8, 2025.
8 October 2025
····
Moderna, Inc. (MRNA) Stock Update – Oct 8 2025: Will the mRNA Trailblazer Bounce Back or Sink Further?

Moderna, Inc. (MRNA) Stock Update – Oct 8 2025: Will the mRNA Trailblazer Bounce Back or Sink Further?

Detailed Report 1. Stock Performance and Valuation Moderna’s stock was a market darling during the pandemic but has suffered a long decline. On Oct 7 2025 (the last trading day before the U.S. Columbus Day holiday), the stock closed at $27.34, down roughly 0.7% from $27.54 on the prior sessionstockinvest.us. Technical analysts at Stockinvest.us noted the shares were near the upper part of a wide falling trend and predicted a possible trading range of $26.40–$28.73 on Oct 8, with longer‑term support around $26 and resistance near $31stockinvest.us. While short‑term signals were positive, they cautioned that the overall downward trend remainsstockinvest.us. Because multiple financial
8 October 2025
·····
Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook

Why Intellia Therapeutics’ Stock Could Be a Gene‑Editing Goldmine in 2025 – Deep Dive into NTLA’s Prospects

Quick Facts (as of 8 Oct 2025) Recent Performance and News Phase 1 data fuels rally Intellia’s October rally was triggered by longer‑term Phase 1 results for nexiguran ziclumeran (nex‑z), an in‑vivo CRISPR therapy for transthyretin (ATTR) amyloidosis. A GlobeNewswire release (Sept 25 2025) reported that a single dose produced a rapid, deep and durable reduction of serum TTR levels—mean reduction 92 % at 24 months and 90 % at 36 monthsglobenewswire.com. Patients also showed clinical improvements or stabilization of neuropathy and cardiac markersglobenewswire.com, and safety findings were mostly mild infusion‑related eventsglobenewswire.com. CEO John Leonard said the data “demonstrate rapid, deep and durable TTR reductions with meaningful clinical improvements” and reiterated
8 October 2025
····
CRISPR Therapeutics Stock Update (Oct 8 2025): Why Gene‑Editing Bulls See Big Upside

CRISPR Therapeutics Stock Update (Oct 8 2025): Why Gene‑Editing Bulls See Big Upside

Stock Price, Volume and Sentiment According to AAII, CRSP’s share price on 8 Oct 2025 closed at $77.727, up 10.06 % from the previous close. The stock traded between $70.77 and $78.38 that day and has risen ~20 % during October. Over the prior year the share price ranged from $30.04 to $73.95, and year‑to‑date performance stood at +97.5 %. Trading volume on INDmoney’s quote was 3.1 million sharesindmoney.com. Fintel’s data as of 7 Oct 2025 list a market cap of roughly $6.2 billion, a beta of 1.32 and a short interest of 26.3 %, suggesting significant volatility and short‑seller interestfintel.io. The average one‑year price target of $81.3 implies modest
8 October 2025
···
Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook

Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook

Intellia at a Glance: CRISPR Trailblazer in 2025 Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a clinical-stage biotechnology company at the forefront of CRISPRgene editing medicines. Headquartered in Cambridge, MA, Intellia was one of the first companies to harness CRISPR-Cas9 technology to develop potential in vivo therapies – treatments delivered directly into the body to edit genes inside patients’ cells. In fact, Intellia reported the first-ever clinical evidence that CRISPR could provide a therapeutic benefit in humans via in-body gene editing, showing in 2021 that a one-time IV infusion could drastically lower a disease-causing protein in patients ts2.tech. This pioneering achievement, accomplished with their transthyretin amyloidosis (ATTR)
8 October 2025
···
TSMC Stock Soars on AI Boom: Record Highs, Big Ambitions & Geopolitical Risks (Oct 2025 Update)

TSMC Stock Soars on AI Boom: Record Highs, Big Ambitions & Geopolitical Risks (Oct 2025 Update)

Overview: TSMC’s Business and Recent Performance Taiwan Semiconductor Manufacturing Co. (TSMC) is the world’s largest contract chipmaker (pure-play foundry), producing advanced semiconductors for clients like Apple, NVIDIA, AMD, and many otherstaiwannews.com.twts2.tech. Rather than selling its own branded chips, TSMC builds chips to order, focusing on cutting-edge manufacturing processes. This model has made TSMC a pillar of global tech supply chains and given it an estimated 60%+ market share of the overall foundry market (and over 90% share in the most advanced nodes)ts2.tech. Financially, TSMC has been on a strong growth trajectory. In Q2 2025, TSMC’s revenue reached US$30.1 billion, a 44%year-on-year surge, with net profit of T$398.3 billion, driven by
8 October 2025
·····
Apple Stock Hits New Heights: iPhone 17 Supercycle, Analyst Split, and 2025 Outlook Revealed

Apple Stock Hits New Heights: iPhone 17 Supercycle, Analyst Split, and 2025 Outlook Revealed

Overview: Apple Inc. and Recent Performance Apple Inc. – the world’s largest company by market capitalization – has had a mixed 2025 so far. With a market cap around $3.8 trillionts2.tech, Apple’s size means even modest growth is hard-fought. Year-to-date, AAPL stock is roughly flat (+~2%), underperforming the broader tech sectorts2.tech. This muted performance comes despite Apple achieving record financial results in 2025 (its June quarter revenue jumped ~10% YoY to $94 billion)ts2.tech. Early in the year the stock sold off amid market rotation and AI hype elsewhere, at one point down ~17%. But a strong rebound in late summer – fueled by booming iPhone sales –
8 October 2025
·····
Cisco’s $2B AI Windfall: New Tech, Stock Surge & What’s Next for CSCO

Cisco’s $2B AI Windfall: New Tech, Stock Surge & What’s Next for CSCO

Cisco’s Business Model & Market Position Cisco Systems is best known as the world’s largest vendor of networking hardware and software, powering much of the internet’s infrastructure. The company’s business model centers on selling network equipment (like routers, switches, and wireless access points), along with security solutions, collaboration tools (e.g. Webex conferencing gear/software), and observability software (monitoring and analytics, bolstered by its 2024 acquisition of Splunk). In addition, Cisco provides a range of services – from technical support and maintenance contracts to cloud-managed software subscriptions. Cisco generates revenue both through direct sales and via a global channel of resellers and distributors, ensuring its products reach enterprises of all sizes and governments worldwidenasdaq.com. This
8 October 2025
···
UnitedHealth Group Stock Surges Amid Analyst Upgrades: Is Wall Street Turning Bullish on UNH in 2025?

UnitedHealth Group Stock Surges Amid Analyst Upgrades: Is Wall Street Turning Bullish on UNH in 2025?

Current Stock Price and Performance (Oct 8 2025) UnitedHealth Group’s share price has been volatile in 2025. On 8 Oct 2025 the stock closed around $372—IndMoney quoted $372.93 while Investing.com listed $372.64indmoney.cominvesting.com. Reuters reported that the last trade was $371.46, up 2.15 % from the previous dayreuters.com. The wide 52‑week range ($234.60‑$630.73) highlights the enormous drawdown from April’s peak and underscores the severity of the 2025 sell‑off. The stock’s average daily trading volume is about 5.9 million shares, and its beta of 0.47 indicates less volatility than the S&P 500reuters.commarketbeat.com. Year‑to‑date performance remains negative (‑28 % to ‑37 % depending on the reference period), but shares have rebounded more
8 October 2025
···
1 … 401 402 403 404 405 … 586

Stock Market Today

Meta stock faces an AI split: ad gains vs a $135 billion bill

Meta stock faces an AI split: ad gains vs a $135 billion bill

7 February 2026
Meta shares dropped 1.3% to $661.46 on Friday after the company projected 2026 capital spending of up to $135 billion, raising investor concerns over cash flow. Meta reported Q4 revenue of $59.89 billion, up 24% year-over-year, with ad impressions rising 18%. Analysts remain divided on whether AI-driven ad gains can offset the steep spending ramp.
Go toTop